Beam Therapeutics (BEAM) Gains from Investment Securities (2019 - 2026)
Beam Therapeutics (BEAM) reported Gains from Investment Securities of -$514000.0 for Q1 2026, down 2003.7% year-over-year from $27000.0 in Q1 2025, and down 194.14% on a QoQ basis from $546000.0 in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of Gains from Investment Securities data on file, last reported at -$514000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 2003.7% year-over-year to -$514000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$941000.0 (down 294.02% YoY) and the FY2025 annual result came in at $11.3 million, up 17.81% from the prior year.
- Gains from Investment Securities fell to -$514000.0 in Q1 2026 per BEAM's latest filing, from $546000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $10.0 million in Q3 2024 and bottomed at -$1.8 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is $433303.5 (2025), against an average of $1.8 million.
- The widest annual swing landed in 2023, when Gains from Investment Securities jumped 798.16%; it then tumbled 2003.7% in 2026.
- Tracing BEAM's Gains from Investment Securities over 5 years: stood at $250000.0 in 2022, then slumped by 748.0% to -$1.6 million in 2023, then surged by 229.88% to $2.1 million in 2024, then sank by 74.05% to $546000.0 in 2025, then tumbled by 194.14% to -$514000.0 in 2026.
- Per Business Quant, the three latest BEAM Gains from Investment Securities figures stand at -$514000.0 (Q1 2026), $546000.0 (Q4 2025), and -$1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -514,000.00 |
| Mar 31, 2026 | -514,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | -1.00 Mn |
| Sep 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | 320,607.00 |
| Jun 30, 2025 | 320,607.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 10.04 Mn |
| Sep 30, 2024 | 10.04 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | 133,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Dec 31, 2023 | -1.62 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 8.83 Mn |
| Jun 30, 2023 | 8.83 Mn |
| Mar 31, 2023 | 603,000.00 |
| Mar 31, 2023 | 603,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Jun 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.76 Mn |
| Mar 31, 2022 | 7.26 Mn |
| Mar 31, 2022 | 7.26 Mn |
| Dec 31, 2021 | -24.23 Mn |
| Dec 31, 2021 | -24.23 Mn |
| Sep 30, 2021 | 6.14 Mn |
| Sep 30, 2021 | 6.14 Mn |
| Jun 30, 2021 | 798,000.00 |
| Jun 30, 2021 | 798,000.00 |
| Mar 31, 2021 | 6.11 Mn |
| Mar 31, 2021 | 6.11 Mn |
| Dec 31, 2020 | 1.51 Mn |
| Dec 31, 2020 | 1.51 Mn |
| Sep 30, 2020 | 1.35 Mn |
| Sep 30, 2020 | 1.35 Mn |
| Jun 30, 2020 | 5.65 Mn |
| Jun 30, 2020 | 5.65 Mn |
| Mar 31, 2020 | 5.66 Mn |
| Mar 31, 2020 | 5.66 Mn |
| Dec 31, 2019 | 1.53 Mn |
| Dec 31, 2019 | 1.53 Mn |
| Sep 30, 2019 | -10,000.00 |
| Sep 30, 2019 | -10,000.00 |
| Mar 31, 2019 | 78,000.00 |
| Mar 31, 2019 | 78,000.00 |